Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

With $46m, i2o Takes Up The Challenge Of Winning Approval For ITCA 650

Aug 28 2023

• By Joseph Haas

Business partners hands on top of each other symbolizing companionship — i2o adds to its pipeline by acquiring Intarcia IP

Related Content

Intarcia, CDER Tussle Over Advisory Cmte. Process For Hearing On Denial Of Diabetes Combo Product

Apr 26 2023

Intarcia Gets Chance For AdComm Review Of ITCA 650; Hearing For Sotagliflozin Shot Down

Feb 12 2023

WTO Price Transparency Talks Face Resistance From Developed Countries

Oct 29 2019

Intarcia's Once-Yearly Diabetes Drug Bests Januvia

Aug 20 2015

Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter

Sep 16 2016

Related Companies

i2O Therapeutics, Inc.

Intarcia Therapeutics, Inc.

Eli Lilly and Company

Novo Nordisk A/S

AstraZeneca PLC

Merck & Co., Inc.

Harvard University

Additional Topics

Deals Business Strategies Financing Commercial Metabolic Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window